Konstantin Penkov
About
Konstantin Penkov is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research.
According to data from OpenAlex, Konstantin Penkov has authored 24 papers receiving a total of 312 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Pulmonary and Respiratory Medicine, 15 papers in Oncology and 8 papers in Cancer Research. Recurrent topics in Konstantin Penkov's work include Renal cell carcinoma treatment (7 papers), Cancer Immunotherapy and Biomarkers (7 papers) and Lung Cancer Treatments and Mutations (7 papers). Konstantin Penkov is often cited by papers focused on Renal cell carcinoma treatment (7 papers), Cancer Immunotherapy and Biomarkers (7 papers) and Lung Cancer Treatments and Mutations (7 papers). Konstantin Penkov collaborates with scholars based in United States, Italy and South Korea. Konstantin Penkov's co-authors include Toni K. Choueiri, John B.A.G. Haanen, Alessandra di Pietro, Robert J. Motzer, James Larkin, Laurence Albigès, Matthew T. Campbell, Sumanta K. Pal, Jae‐Lyun Lee and Paul B. Robbins and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.
In The Last Decade
Konstantin Penkov
23 papers receiving 305 citations
Peers
Konstantin Penkov
Alketa Hamzaj Italy
C. Suárez Rodríguez Spain
Niels Viggo Jensen Denmark
Jahangeer Malik United Kingdom
Craig Norton United States
Antonio Santaniello Italy
Benjamin Miron United States
Daniela Cullurà Italy
L Morrissey United States
T-E. Ciuleanu Romania
Citations per year, relative to Konstantin Penkov Konstantin Penkov (= 1×)
peers
Alketa Hamzaj
Countries citing papers authored by Konstantin Penkov
Since
Specialization
Citations
This map shows the geographic impact of Konstantin Penkov's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Konstantin Penkov with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Konstantin Penkov more than expected).
Fields of papers citing papers by Konstantin Penkov
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Konstantin Penkov. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Konstantin Penkov. The network helps show where Konstantin Penkov may publish in the future.
Co-authorship network of co-authors of Konstantin Penkov
This figure shows the co-authorship network connecting the top 25 collaborators of Konstantin Penkov. A scholar is included among the top collaborators of Konstantin Penkov based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Konstantin Penkov. Konstantin Penkov is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Schweizer, Michael T., Mariona Calvo, Víctor Moreno, et al.. (2025). Mevrometostat (PF-06821497), an enhancer of zeste homolog 2 (EZH2) inhibitor, in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC): A randomized dose-expansion study.. Journal of Clinical Oncology. 43(5_suppl).
2.
Schweizer, Michael T., Konstantin Penkov, Atish D. Choudhury, et al.. (2024). Phase 1 trial of mevrometostat (PF-06821497), a potent and selective inhibitor of enhancer of zeste homolog 2 (EZH2), in castration-resistant prostate cancer (CRPC).. Journal of Clinical Oncology. 42(16_suppl). 5061–5061.
3.
Wysocki, Piotr J., Kyung Hae Jung, Do‐Youn Oh, et al.. (2024). Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: Results from the bladder cohort of the DESTINY-PanTumor02 (DP-02) study.. Journal of Clinical Oncology. 42(16_suppl). 4565–4565.
4.
Oh, Do‐Youn, Iwona Ługowska, Daniil Stroyakovskiy, et al.. (2024). Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing biliary tract cancer (BTC) and pancreatic cancer (PC): Outcomes from DESTINY-PanTumor02 (DP-02).. Journal of Clinical Oncology. 42(16_suppl). 4090–4090.
5.
Motzer, Robert J., Konstantin Penkov, Hirotsugu Uemura, et al.. (2024). Avelumab + axitinib vs sunitinib in patients (pts) with advanced renal cell carcinoma (aRCC): Final overall survival (OS) analysis from the JAVELIN Renal 101 phase 3 trial.. Journal of Clinical Oncology. 42(16_suppl). 4508–4508.
6.
Cho, Byoung Chul, Konstantin Penkov, Igor Bondarenko, et al.. (2023). A phase Ib/II dose expansion study of subcutaneous sasanlimab in patients with locally advanced or metastatic non-small-cell lung cancer and urothelial carcinoma. ESMO Open. 8(4). 101589–101589.
7.
Bearz, Alessandra, Jean‐François Martini, Jacek Jassem, et al.. (2023). Efficacy of Lorlatinib in Treatment-Naive Patients With ALK-Positive Advanced NSCLC in Relation to EML4::ALK Variant Type and ALK With or Without TP53 Mutations. Journal of Thoracic Oncology. 18(11). 1581–1593.
8.
Haanen, John B.A.G., James Larkin, Toni K. Choueiri, et al.. (2023). Extended follow-up from JAVELIN Renal 101: subgroup analysis of avelumab plus axitinib versus sunitinib by the International Metastatic Renal Cell Carcinoma Database Consortium risk group in patients with advanced renal cell carcinoma. ESMO Open. 8(3). 101210–101210.
9.
Hamilton, Erika, Komal Jhaveri, Sherene Loi, et al.. (2023). Abstract PD18-11: Dose-Expansion Study of Trastuzumab Deruxtecan as Monotherapy or Combined With Pertuzumab in Patients With Metastatic Human Epidermal Growth Factor Receptor 2-Positive (HER2+) Breast Cancer in DESTINY-Breast07 (DB-07). Cancer Research. 83(5_Supplement). PD18–11.
10.
Calvo, Mariona, Konstantin Penkov, Alexander I. Spira, et al.. (2023). A multi-center, open-label, randomized dose expansion study of PF-06821497, a potent and selective inhibitor of enhancer of zeste homolog 2 (EZH2), in patients with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 41(6_suppl). TPS282–TPS282.
11.
Bearz, Alessandra, Jean‐François Martini, Jacek Jassem, et al.. (2022). Phase 3 trial of lorlatinib in treatment-naive patients (Pts) with ALK-positive advanced non–small cell lung cancer (NSCLC): Comprehensive plasma and tumor genomic analyses.. Journal of Clinical Oncology. 40(16_suppl). 9070–9070.
12.
Byers, Lauren A., Dmitry Bentsion, Steven Gans, et al.. (2021). Veliparib in Combination with Carboplatin and Etoposide in Patients with Treatment-Naïve Extensive-Stage Small Cell Lung Cancer: A Phase 2 Randomized Study. Clinical Cancer Research. 27(14). 3884–3895.
13.
Makharadze, Tamta, Ruben G.W. Quek, Tamar Melkadze, et al.. (2021). 93P Patient-reported outcomes (PROs) with cemiplimab or placebo plus platinum-doublet chemotherapy (chemo) for first-line (1L) treatment of advanced non-small cell lung cancer (aNSCLC): EMPOWER-Lung 3 trial. Annals of Oncology. 32. S1414–S1414.
14.
Solomon, Benjamin, Tony Mok, Hidetoshi Hayashi, et al.. (2021). 1199P Dose modification for the management of CNS adverse events in the phase III CROWN study of lorlatinib in non-small cell lung cancer (NSCLC). Annals of Oncology. 32. S957–S958.
15.
Bearz, Alessandra, Jean‐François Martini, Jacek Jassem, et al.. (2021). Abstract LB043: Efficacy of Lorlatinib in Treatment-Naïve Patients (pts) With ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) in Relation to EML4-ALK Variant Type and ALK Mutations. Cancer Research. 81(13_Supplement). LB043–LB043.
16.
Gogishvili, Miranda, Tamar Melkadze, Tamta Makharadze, et al.. (2021). LBA51 EMPOWER-Lung 3: Cemiplimab in combination with platinum doublet chemotherapy for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC). Annals of Oncology. 32. S1328–S1328.
17.
Penkov, Konstantin, et al.. (2020). 1055P Updated results of subcutaneous (SC) anti-programmed cell death 1 (PD-1) receptor antibody PF-06801591 for locally advanced or metastatic non-small cell lung cancer (NSCLC) or urothelial carcinoma (UC). Annals of Oncology. 31. S721–S721.
18.
Tannir, Nizar M., Neeraj Agarwal, Sumanta K. Pal, et al.. (2020). PIVOT-09: A phase III randomized open-label study of bempegaldesleukin (NKTR-214) plus nivolumab versus sunitinib or cabozantinib (investigator's choice) in patients with previously untreated advanced renal cell carcinoma (RCC).. Journal of Clinical Oncology. 38(6_suppl). TPS763–TPS763.
19.
Choueiri, Toni K., Laurence Albigès, John B.A.G. Haanen, et al.. (2019). Biomarker analyses from JAVELIN Renal 101: Avelumab + axitinib (A+Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC).. Journal of Clinical Oncology. 37(15_suppl). 101–101.
20.
Motzer, Robert J., Konstantin Penkov, John B.A.G. Haanen, et al.. (2018). JAVELIN renal 101: A randomized, phase III study of avelumab + axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma (aRCC). Annals of Oncology. 29. viii724–viii724.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Alketa Hamzaj Breakdown of academic impact, for papers by C. Suárez Rodríguez Breakdown of academic impact, for papers by Niels Viggo Jensen Breakdown of academic impact, for papers by Jahangeer Malik Breakdown of academic impact, for papers by Craig Norton Breakdown of academic impact, for papers by Antonio Santaniello Breakdown of academic impact, for papers by Benjamin Miron Breakdown of academic impact, for papers by Daniela Cullurà Breakdown of academic impact, for papers by L Morrissey Breakdown of academic impact, for papers by T-E. Ciuleanu